

Date	Presenter	Title	Journal	Year	Vol	Page
7月3日	榊	Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial	Lancet Oncology	2018	19	871-879
	長井	Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment.	Cell stem cell	2018	22	600-607
7月10日	一瀬	Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients	Blood	2018	131	1698-1703
	沢山	Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT	Blood	2018	131	2978-2986.
7月17日	古本	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.	Lancet Oncology	2018	19	889-903
	学生	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.	Blood	2018	132	49-58
7月24日	田口	Somatic mutations precede acute myeloid leukemia years before diagnosis	Nature medicine	2018	24	1015-1023
		prediction of acute myeloid leukemia risk in healthy individuals	Nature	2018	559	400-404
	宮崎	Consequences of mutant TET2 on clonality and subclonal hierarchy	Leukemia	2018	32	1751-1761
7月31日	北之園	Epigenetic silencing of miR-125b is required for normal B-cell development	Blood	2018	131	1920-1930
	今泉	JCOG班会議の報告				
9月4日	北之園	BET Inhibition-Induced GSK3 β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.	Cell report	2018	24	2155-2166
	糸永	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?	Leukemia	2018	32	1482-1492
9月11日	榊	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.	Am J Hematology	2018	93	921-930
	佐藤	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.	N Engl J Med	2018	379	811-822
9月18日	藤岡	日本血液学会予行				
9月25日	橋本	日本血液学会予行				
	坂本	日本血液学会予行				
10月2日	一瀬	Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.	J Clin Oncol.	2017	35	32-39
	波多	日本血液学会予行				
10月9日	古本	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma	N Engl J Med	2018	379	934-947
	安東	Small Molecules Co-targeting CKI α and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.	Cell	2018	175	171-185
10月16日		血液学会 報告会				
10月23日	田口	Population dynamics of normal human blood inferred from somatic mutations	Nature	2018	561	473-478
	波多	Relative survival following response to 7 + 3 versus azacitidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.	Leukemia	2018		
10月30日	長井	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.	Blood Adv.	2018	23	2619-2628
	藤岡	Lymphocyte-Area Under the Curve as a predictive factor for viral infection after allogenic hematopoietic stem cell transplantation.	Biol Blood Marrow Transplant.	2018		
11月6日	坂本	Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.	Blood.	2018	131	1522-1531
	澤山	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation.	Biol Blood Marrow Transplant.	2018	24	1463-1470.
11月13日	田口	ASH予行				
	今泉	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.	Cancer Cell.	2018	34	286-297
11月20日	北之園	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival	Blood.	2018	132	2026-2039
	宮崎	ASHの講演内容の紹介				
11月27日	榊	Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.	J Clin Oncol.	2018	36	2918-2925
	佐藤	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML	N Engl J Med	2018	378	2386-2398